ERBB2 and breast carcinoma: Comparatively, ‘triple negative’ breast cancers lacking hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2) typically have less treatment options and a higher recurrence rate and thus poorer outcome [7].